Summary Of 311 colorectal cancers diagnosed in 1984-86 in the county of Ostergotland, Sweden, 179 were included in a case-control study, and, of these, 70 were investigated using immunohistochemical staining for p53 gene mutations. Alcohol use as well as medication with hydralazine-containing antihypertensive drugs, but not heredity were associated with p53 staining. The study is offered to illustrate the possible value of investigating molecularly defined tumour subtypes in relation to specific risk factors.
Colorectal cancer has been the subject of many epidemiological and experimental studies mainly focusing on its relation to dietary factors, although several have also addressed the subject of occupational exposures (Potter et al., 1993) . Colorectal cancer has turned out to be an excellent system for studying mutations and target genes in the development and progression of human cancer (Fearon and Vogelstein, 1990) . The tumour-suppressor gene p53 is frequently mutated and inactivated in colorectal cancers as in about half of all types of cancer (Greenblatt et al., 1994) . Neoplastic cells carrying missense mutations in exons 5 -8 of the p53 gene are easily detected with an immunohistochemical technique (immunostaining) because most of these mutations are associated with a dramatically increased half-life of the p53 protein (Rodrigues et al., 1990; Levine et al., 1991) . In contrast, the p53 protein level is low in normal cells and essentially undetectable by immunohistochemical techniques.
In this pilot study, we have combined molecular genetic data with epidemiological to investigate specific risk factors and their possible mechanisms of action in colorectal cancer, as previously proposed (Axelson and Soderkvist, 1991) .
Materials and methods
The data in this study are derived from two different studies, each considering colorectal cancer in the county of Ostergotland, Sweden. The first of these is a case-control study (Arbman et al., 1993) Seventy cases, 29 with staining and 41 without staining (five cases with only cytoplasmic staining were excluded), were present in both studies and were compared with the controls, following a study design described elsewhere (Axelson and S6derkvist, 1991; Axelson, 1994) . The exposures considered here have all been associated with a colorectal cancer risk in other studies.
Odds ratios (OR), adjusted for age and sex, along with 95% confidence intervals (CI95) were calculated by logistic regression. Since sedentary work has been associated with increased risk for colorectal cancer, a variable for physical activity was included as described by Vena et al. (1985) .
Results
Among the 70 cases with colorectal cancer, 29 (42%) revealed p53-positive staining with similar sex distribution for p53-positive and p53-negative tumours. The mean age was 64 years for both p53-positive cases and p53-negative cases versus 58 years for controls, differences adjusted for in the analysis. Thirty-eight (54%) of the cases had colon cancer and 32 (46%) had rectal cancer. Among the p53-negative cases 24 (58%) had colon cancer. With regard to p53 positivity, 14 (48%) of the 29 had colon cancer.
In contrast to some other studies (Potter et al., 1993) , no overall risk from alcohol consumption can be seen in this study, but when p53 status was considered, an increased risk for p53-positive tumours and alcohol intake was indicated (OR = 3.4, C195 1.1 -10), but not for p53-negative cases, (OR=0.61 C195 0.3-1.2) ( The overall risk for colorectal cancer and intake of drugs for iron supplementation was elevated (OR= 4.9, C195 1.1-21) in this study and even more for p53-negative cases (OR=8.7, C195 2.0-38). Sedentary work appeared with a low risk for the p53-positive cases (OR=0.71, C195 0.2-2.1 for > 20 years of sedentary work) ( Table I ). The earlier found increased risk for sedentary work for more than 20 years (Arbman et al., 1993) , was carried by the p53-negative cases (OR= 1.6, C195 0.7-3.5) in this study.
Cases reporting colorectal cancers among close relatives (parent, sibling or children), and who might therefore be members of a family with a hereditary form or colorectal cancer (i.e. familial adenomatous polyposis or hereditary non-polyposis colon carcinoma) were all p53 negative (OR=5.7, C195 1.9-17).
Discussion
The numbers are small in this study, but nevertheless, the observed distribution of p53-positive and p53-negative cases in relation to exposure might reflect different pathways in the carcinogenic process. The frequency of p53-positive cases (42%) is almost the same as in the prognostic study (39%) (Sun et al., 1992) , suggesting that p53 distribution per se is not skewed among the cases despite limited numbers.
Another weakness of this study could be that positively stained tumours are occasionally found that do not carry any missense mutations. This suggests that there are also alternative mechanisms for abnormal stabilisation of the p53 protein, such as binding with cellular proteins or increased gene expression (Greenblatt et al., 1994; Levine et al., 1991) . Furthermore, frame shift or chain-terminating mutations in the coding sequences often result in an absent, unstable or truncated protein, which is undetectable by immunostaining. Therefore, immunoreactivity appears as an approximate indicator of tumours for an altered p53 gene function. More conclusive results can only be obtained after sequencing of the gene and/or functional assays (Ishioka et al., 1993) .
Although no overall risk from alcohol appeared as was the case in other studies (Potter et al., 1993) , the separate analysis revealed an increased risk for p53-stained tumours (Table I) . Medication with antihypertensive drugs containing hydralazine showed an association with p53 positivity. Antihypertensive medication has also appeared as a risk factor for colon and rectal cancer in earlier case -control studies, (Axelson et al., 1982; Kaufman et al., 1989) . Hydralazine is mutagenic and carcinogenic (Toth, 1978) and induces DNA damage after enzymatic activation, possibly due to formation of a hydralazyl radical (Yamamoto, 1991) . Hydralazine may therefore induce mutations in the p53 gene in colonic cells, stimulating tumour growth or selectively promoting the growth of p53-mutated colonic cells (and the same may be true for alcohol).
Colon cancer has been associated with high iron stores in the body (Stevens et al., 1988) , which to some extent might support the possibility of an increased risk from iron supplementation as found in this study. There was no inactivation of the p53 gene with regard to iron supplementation, so to the extent that our data reflect a true relationship, there may instead be an activation of proto-oncogenes or inactivation of other tumour-suppressor genes or some epigenetic mechanism.
The decreased risk for the p53-positive cases in relation to sedentary work is somewhat surprising, since sedentary work, or low physical activity, is normally considered to be a risk factor for colon cancer (Arbman et al., 1993; Fredrikson et al., 1989; Vena et al., 1985; Potter et al., 1993) . In the original case-control study (Arbman et al., 1993) , sedentary work was associated with a decreased risk for rectal cancer whereas an increased risk was seen for colon cancer.
Recently, the genes responsible for both familial adenomatous polyposis and hereditary non-polyposis colon carcinoma have been identified (Kinzler et al., 1991; Groden et al., 1991; Altonen et al., 1993; Ionov et al., 1993 p53 mutated cases represent exposures that are important for promotion or progression rather than initiation of the carcinogenic process. Recent studies also show a remarkably specific interaction between certain environmental carcinogens and mutational patterns in the p53-gene (Greenblatt et al., 1994) . So-called molecular epidemiology, as illustrated here, is likely to become a powerful technique for studying critical target genes and mutational patterns in different genes, such as p53, in relation to certain exposures. Such studies may reveal exposures associated with molecularly defined tumour subtypes and also provide a better understanding of tumour pathogenesis.
